MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 بازدیدها
administrator
07/09/23
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
بیشتر نشان بده، اطلاعات بیشتر
نظرات فیس بوک
نظری یافت نشد